论文部分内容阅读
目的 探讨还原型谷胱甘肽 (古拉定 ,GLT)对帕金森病人治疗效果 ,观察GLT治疗后病人血超氧化物歧化酶 (SOD)、谷胱甘肽过氧化酶 (GSH Px)、丙二醛 (MDA)水平的变化。方法 选择 30例临床未治疗或服用美多巴因副反应被迫减药病人 ,应用GLT进行治疗 ,治疗前后行血SOD、GSH PX、MDA测定 ,并设立对照组、正常人组比较 ;治疗、Px对照组进行了治疗前后H Y分级及Webster评分。结果 治疗组和正常人组比较 ,血SOD、GSH Px显著减低 (P <0 0 1) ,MDA显著增高 (P <0 0 1) ;GLT治疗后 ,SOD、GSH Px值较治疗前明显升高 (P <0 0 5、P <0 0 1) ,MDA值下降 (P <0 0 5 ) ,而对照组改变不明显。治疗前后评分 ,治疗后临床症状有显著改善 (P <0 0 1) ,与对照组比较 ,两组有显著差异 (P <0 0 1)。结论 GLT对PD病人有较显著治疗作用。
Objective To investigate the therapeutic effect of reduced glutathione (GLT) on Parkinson’s disease and to observe the changes of serum superoxide dismutase (SOD), glutathione peroxidase (GSH Px), glutathione peroxidase Changes in dialdehyde (MDA) levels. Methods Thirty patients with clinical or untreated clinical symptoms were treated with GLT for 20 days. The levels of serum SOD, GSH PX and MDA were measured before and after treatment. The patients in control group and normal group were treated with GLT, Px control group before and after HY classification and Webster score. Results Compared with the normal control group, the levels of SOD and GSH Px in the blood were significantly decreased (P <0.01) and the MDA levels were significantly increased (P <0.01). After GLT treatment, the Px values of SOD and GSH were significantly increased (P <0.05, P <0.01), MDA decreased (P <0.05), while the control group did not change significantly. Before and after treatment, clinical symptoms were significantly improved after treatment (P <0.01). There was significant difference between the two groups (P <0.01). Conclusion GLT has a significant therapeutic effect on PD patients.